Status:

COMPLETED

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Chronic Hepatitis C Genotype-1 Relapse

Eligibility:

All Genders

18-69 years

Phase:

PHASE2

Brief Summary

This is a study designed to identify a dose of NIM811 that has a good safety profile, is well tolerated when co-administered with SOC, and provides a clinically meaningful effect in viral load reducti...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Patients eligible for inclusion in this study have to fulfill all of the following criteria:
  • chronic hepatitis C genotype-1
  • HCV-RNA should be ≥ 4 x 105 IU/mL at screening
  • Recipient of prior long acting interferon and ribavirin treatment for at least 12 weeks, with documented negative serum HCV RNA on treatment, who subsequently becomes serum HCV RNA positive after stopping treatment ("relapser"). Patients must have been off all treatment for at least 3 months prior to start of study (Visit
  • Exclusion criteria:
  • Use of any HCV treatment ≤ 3months prior to study start
  • Prior receipt of any investigational anti-HCV therapy which is not IFN or RBV
  • Women of child-bearing potential unless they are post-menopausal or use predefined acceptable methods of contraception
  • Pregnant or breastfeeding women
  • Evidence of cirrhosis, hepatic decompensation, other than HCV liver disease, HBV or HIV infection
  • Specified abnormalities in lab values of amongst others hemoglobin, WBC, ANC, platelets
  • History of treatment for depression
  • Steroid/immunosuppression drug use 3 months prior to study start Other protocol-defined inclusion/exclusion criteria may apply

Exclusion

    Key Trial Info

    Start Date :

    September 1 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    Estimated Enrollment :

    59 Patients enrolled

    Trial Details

    Trial ID

    NCT00983060

    Start Date

    September 1 2009

    Last Update

    December 19 2020

    Active Locations (16)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 4 (16 locations)

    1

    Research and Education Inc.

    San Diego, California, United States, 92105

    2

    Orlando Clinical Research Center

    Orlando, Florida, United States, 32809

    3

    University Hepatitis Center

    Sarasota, Florida, United States, 34243

    4

    West Wind'r Research & Development LLC

    Tampa, Florida, United States, 33607